Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMM2NSK)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine
| |||||
| Therapeutic Class | Antiarrhythmic Agents | |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Breast epithelium
Normal
Cervix
Cervical adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Normal (Transformed)
Lung
Lung adenocarcinoma
Pancreas
Pancreatic carcinoma
Peripheral blood
Acute monocytic leukemia
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
Umbilical vein
Normal
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
